Plasma metabolomic and Growth Differentiation Factor-15 (GDF-15) in chronic heart failure with physical frailty
Discuss this preprint
Start a discussion What are Sciety discussions?Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Background
chronic heart failure (HF) is a disease intertwined physical frailty are highly common. Investigating metabolic features and pathways associated with HF-Frailty can provide insight into molecular mechanisms, identify subphenotypes, and suggest potential therapeutic targets.
Methods
we collected data from total of 25 with chronic HF (mean age 67.9 ± 10.0 years) and 29 NonHF (mean age 67.8 ± 11.1 years). Physical frailty was assessed using low physical activity level in presence of low handgrip strength and/or 30-second chair stand test. Untargeted metabolomic profiling was performed. Plasma biomarkers including Growth Differentiation Factor (GDF)-15, were quantified. Statistical analyses were conducted via SPSS and MetaboAnalyst.
Results
The HF-Frail (n=25) compared to NonHF-NonFrail (n=18), had higher fat free mass (33.3 vs. 20.8 kg, P<0.01), but lower appendicular lean soft tissue to (22.8 vs. 20.2 P=0. 0.03), lower 6-miutes walking distance (386.4 vs. 501.3 meters, P<0.01), less 30-second chair stand repetitions (9.2 vs. 14.2, P<0.01), and weaker hand grip strength/BMI (1.05 vs. 1.41, P=0.035). HF-Frail compared to NonHF-NonFrail had significantly elevated plasma NT-proBNP (241.2 vs. 117.1 pg/ml, P=0.007), GDF-15 levels (1227.2 vs. 382.5 pg/ml, P<0.01). Agnostic principal component analysis revealed a distinct metabolic profile between HF-Frail compared to NonHF-NonFrail. HF-Frail showed elevated hexadecenoic acid, branched-chain amino acids, and glycolytic metabolites, with reduced glutamine and methionine and lower tryptophan and indole-3-acetamide, and higher tricarboxylic acid intermediates (e.g., citric acid, and glutaric acid-2oxo), compared to NonHF-NonFrail controls. Compared to HF-NonFrail, HF-Frail had lower galacturonic acid-1-phosphate, methionine, indole-3-acetamide, and energy metabolism intermediates (e.g., pyruvic acid, malic acid), but higher 2-hydroxy-glutaric acid. Similarly, pathway analysis revealed also enrichment of urea amino acid metabolism, fatty acids and BCAA degradations.
Conclusions
HF-Frail compared to NonHF-NonFrail showed exacerbated impaired energy metabolism, reduced ability to replenish excess tricarboxylic acids intermediates, alongside elevated inflammation and GDF-15, at least partly, indicate high systemic catabolism.
